Global WholeHealth Partners, Corp. (OTC: GWHP) Confirms Their Antibody Test Kit Detects Fast Spreading Mutated COVID-19 Strains, UK (B.1.1.7) and South Africa (B.1.351)
Global WholeHealth Partners Corp. (OTC: GWHP) is addressing the spread of the highly contagious UK COVID-19 variant (B.1.1.7) in the U.S. and confirms that their antibody test kit can detect this mutation. As the pandemic strains the country's testing capacity, GWHP emphasizes the need for rapid testing solutions, reporting the ability to deliver up to 1 million tests per day. The company continues to focus on developing and providing FDA-approved diagnostic tests, aiming to combat COVID-19 effectively amid increasing infection rates.
- GWHP confirms its antibody test can detect the highly contagious UK COVID-19 variant.
- The company can deliver up to 1 million tests per day, addressing the urgent testing needs.
- The spread of COVID-19 variants adds urgency but could also increase operational challenges.
- There is intense competition in the medical device industry from larger companies.
“More Highly Contagious COVID-19 Strain” quickly spreading throughout the US and the rest of the world
San Clemente, CA, Feb. 11, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Global WholeHealth Partners Corp. (OTC: GWHP), a multinational supplier of over 70+ FDA approved tests including Dengue, Ebola, Zika, Malaria and also offering one of the largest lines of tests for CoViD19 SARS2, is prepared to help in the fight against CoViD19 SARS2. With the pandemic out of control in the United States, the nation's coronavirus testing system is starting to strain again.
With the new “More Highly Contagious COVID-19 Strain” quickly spreading throughout the US and the rest of the world, Global WholeHealth Partners, Corp (OTC:GWHP) Confirms Their Antibody Test Kit Detects the Mutated COVID-19 Strain. The UK strain (B.1.1.7) has been detected in San Clemente, CA, the home of Global.
The U.K. variant of SARS-CoV-2, known as B.1.1.7., was first discovered in the U.S., in the state of Colorado, at the end of last year. Since then, 690 cases have been detected across 33 states, the Centers for Disease Control and Prevention reports. California has the second most reported cases in the country, behind Florida, with 150. Of those, the majority of infections have been diagnosed in San Diego County, according to Dr. Clayton Chau, the county’s health officer.
Although currently available vaccines appear to be effective against most of the coronavirus variants that have been identified to this point, the strain fueling a resurgence of COVID-19 in South Africa (B.1.351) was not slowed down by vaccines developed … Newsom said “one of the cases was found in Alameda County and the other in Santa Clara County.”
So far, only six cases of a South African variant of the coronavirus have been reported in the U.S., but concern among experts is growing, as emerging data suggests available vaccines may not protect as well against it.
“There is no better way to Stop the Spread of COVID-19 and its various mutated strains then by utilizing the rapid antibody test or antigen test kits that we offer to accurately detect those who have become infected and having them immediately quarantine,” says Charles Strongo, CEO of Global WholeHealth Partners, Corp. “With some of the variants being resistant to vaccines, like the South Africa strain B.1.351, testing more people and following the CDC guidelines is the way to win this war on COVID.”
Global WholeHealth Partners recognizes that there is a crucial need for faster testing and faster results when it comes to fighting the COVID. Global WholeHealth Partners knows that the quicker the test results can be reviewed by a Front-Line Healthcare Worker, the quicker we can stop the spread of this disease.
With results in minutes versus hours or days with other diagnostic kits, the more lives that can be saved with the only FDA authorized COVID-19 POC serology Point of Care Test. With the new fingerstick test, healthcare providers can prick a patient’s finger and get results in minutes without having to wait for venous blood. Global WholeHealth Partners will be able to distribute these tests to more urgent cares, hospitals, and – to help curb the spread of CoViD19 SARS2.
As a third surge of the coronavirus threatens much of the United States, public health experts across the country say there still aren’t enough tests available to keep the virus under control.
About 30 million Covid-19 tests are given every month, according to estimates from The Atlantic magazine’s Covid Tracking Project. But studies have found that the U.S. would need millions more — 193 million a month, according to one report — to be effective.
The USA has the largest number of Covid-19 cases in the world and there is concern that this next wave of infections will be worse than the previous. Global WholeHealth Partners, Corp. is confident that its Covid-19 Rapid Test can make a difference through assisting companies, staff, and public places where transmission may occur with a reliable, accurate, and fast Rapid Test.
Global WholeHealth Partners Corp. provides cutting edge technology using In-vitro Diagnostic (IVD) Real-Time PCR Machines for detection of SARS-CoV-2 IgM/IgG antibodies in human serum, plasma, or whole blood. It has led the fight against vector borne terminal diseases such as Ebola, ZIKA, Dengue, Malaria, Influenza and Tuberculosis, Corona Viruses, and among other vector borne diseases. The company was founded on March 7, 2013 and is headquartered in San Clemente, CA.
GWHP develops, manufactures, and markets in vitro diagnostic (IVD) tests for OTC, or consumer-use as well as professional rapid diagnostic point-of-care (POC) test kits for hospitals, physicians’ offices, and medical clinics in the US and abroad. Notably, GWHP offers a CE Mark for its high quality, rapid antibody test for COVID-19 and an EUA filing with the FDA is pending approval. In the interim, the US Navy in California has been using the test during 2Q20 and the Company has the capacity to deliver hundreds of thousands of tests, ramping up to 1 million per day. Currently, the Company has 56 products FDA approved and many are Approved for OTC use, and 9 POC products approved by the FDA.
Disclaimer:
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.
Media Contact:
Name: Charles Strongo,
CEO, Global WholeHealth Partners Corp.
Email: investors@gwhpcorp.com
https://www.worldometers.info/coronavirus/country/us/
https://www.nbcnews.com/health/health-news/there-still-aren-t-enough-covid-19-tests-u-s-n1243787
www.worldometers.info (https://www.worldometers.info/coronavirus/country/us/)
United States Coronavirus: 27,897,214 Cases and 483,200 Deaths - Worldometer
United States Coronavirus update with statistics and graphs: total and new cases, and deaths per day.
https://www.prevention.com/health/a35031411/britain-covid-19-coronavirus-mutation/
https://www.nbcnews.com/news/us-news/covid-19-testing-capacity-strained-surge-demand-n1249592
Forward-Looking Statements
This press release contains "forward-looking statements.” Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
FAQ
What is Global WholeHealth Partners Corp's role in COVID-19 testing?
How many COVID-19 tests can GWHP deliver per day?
What does GWHP confirm about its antibody test kit?
What challenges does GWHP face amid the COVID-19 variant spread?
